Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in T2D Patients with CAD
NCT07073053Phase 4Not yet recruiting
- Sponsor
- Taipei Veterans General Hospital
- Start
- Oct 2025
- Primary completion
- Jul 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), sponsored by Taipei Veterans General Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07073053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073053.